Search

Displaying results 4131 - 4140 of 10000 in total
  1. Drug

    Amlexanox

    go.drugbank.com/drugs/DB01025
    ApprovedWithdrawn

    Amlexanox is an antiallergic drug, clinically effective for atopic diseases, especially allergic asthma and rhinitis. … Recurrent aphthous ulcer (RAU) is the most prevalent oral mucosal disease in humans, estimated to affect between 5% and 50% of the general population.

    Categories: Alimentary Tract and Metabolism
  2. Drug

    Methylphenobarbital

    go.drugbank.com/drugs/DB00849
    Approved

    It has been used for similar purposes, especially in epilepsy, but there is no evidence mephobarbital offers any advantage over phenobarbital.

    Categories: Barbiturates and Derivatives, Hypnotics and Sedatives
  3. Drug

    Brasofensine

    go.drugbank.com/drugs/DB04857
    Experimental

    Brasofensine is an orally administered dopamine reuptake inhibitor being developed for the treatment of Parkinson's Disease. Phase I/II trials for brasofensine have been completed in the U.K.

  4. Drug

    Paromomycin

    go.drugbank.com/drugs/DB01421
    ApprovedInvestigational

    An oligosaccharide antibiotic produced by various streptomyces. [PubChem]

    Categories: Alimentary Tract and Metabolism
  5. Drug

    GPI-0100

    go.drugbank.com/drugs/DB05929
    Investigational

    The GPI-0100 adjuvant, which has been shown to significantly enhance the immune response with a variety of vaccines, has been shown to have good overall performance characteristics on safety and efficacy

  6. Drug

    Pertuzumab

    go.drugbank.com/drugs/DB06366
    ApprovedInvestigational

    It was first approved by the FDA in 2012 for use with [docetaxel] and another HER2-targeted monoclonal antibody, [trastuzumab], in the treatment of metastatic HER2-positive breast cancer. … It consists of two heavy chains and two lights chains that have 448 and 214 residues respectively.

    Categories: Amino Acids, Peptides, and Proteins, pertuzumab and trastuzumab
  7. Drug

    Triclabendazole

    go.drugbank.com/drugs/DB12245
    ApprovedInvestigational

    Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans. … Triclabendazole was previously used in the treatment of fascioliasis in livestock, but is now approved for human use.

    Categories: Antiparasitic Products, Insecticides and Repellents
  8. Drug

    Inebilizumab

    go.drugbank.com/drugs/DB12530
    ApprovedInvestigational

    Inebilizumab is cytolytic, resulting in B-cell depletion and offering therapeutic benefit to patients suffering from NMOSD. … [L49861] In April 2025, inebilizumab was additionally approved by the FDA for immunoglobulin G4-related disease (IgG4-RD).[L52705,L14315] It is the first and only FDA-approved treatment for IgG4-RD.

    Categories: Amino Acids, Peptides, and Proteins, Antineoplastic and Immunomodulating Agents
  9. Drug

    Dihydroergocristine

    go.drugbank.com/drugs/DB13345
    Approved

    [L2637] It is a semisynthetic ergot alkaloid and thus, it is characterized by a structural skeleton formed by an alkaloid ergoline.

    Categories: Ergot Alkaloids and Derivatives
  10. Drug

    Aglatimagene besadenovec

    go.drugbank.com/drugs/DB15074
    Investigational

    Aglatimagene besadenovec is under investigation in clinical trial NCT00638612 (AdV-tk Therapy With Surgery and Chemoradiation for Pancreas Cancer (PaTK01)).

    Synonyms: ADV-TK